Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Becton Dickinson (NY:BDX)

174.43 -3.07 (-1.73%)
Streaming Delayed Price Updated: 11:20 AM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Becton Dickinson

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
The Best High Yield Medical Device Stock to Invest $1,000 in Right Now
Via The Motley Fool
3 of Wall Street’s Favorite Stocks with Mounting Challenges
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
1 Cash-Producing Stock Worth Your Attention and 2 to Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
Becton Dickinson Stock (BDX): Why It's Best To Avoid For Now
Becton Dickinson stock (BDX): Signs point toward continued underperformance until early June 2027. 
Via Benzinga
How Is The Market Feeling About Becton Dickinson?
Via Benzinga
Earnings Scheduled For May 1, 2025
Via Benzinga
New Jersey Rep. Thomas Kean Bought Over $4K Worth of Amazon.com Stock: Here's What You Should Know
Via Benzinga
3 Healthcare Stocks Skating on Thin Ice
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
3 Value Stocks Facing Headwinds
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
6 Analysts Have This To Say About Becton Dickinson
Via Benzinga
3 Dawdling Stocks with Questionable Fundamentals
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
BDX Q1 Earnings Call: Missed Revenue Expectations, Margin Expansion, and Strategic U.S. Investments
Medical technology company Becton, Dickinson and Company (NYSE:BDX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 4.5% year on year to $5.27 billion. On the other hand, the... 
Via StockStory
Topics Economy World Trade
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?
Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April. 
Via Benzinga
Topics Stocks
3 Profitable Stocks with Questionable Fundamentals
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing. 
Via Benzinga
Block, Becton Dickinson And Pilgrim's Pride Are Among Top 10 Large-Cap Losers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Via Benzinga
Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years
Becton Dickinson receives multiple downgrades as analysts cite weakening organic growth and trimmed price targets following a Q2 update. 
Via Benzinga
Wall Street Fully Recoups Tariff-Led Losses, Economy Contracts In First Quarter Yet April Payrolls Remain Strong: This Week In Markets
Via Benzinga
Topics Economy
Wall Street Roars Back From April Tariff Sell-Off: Which Sectors Are Still Underwater?
Via Benzinga
This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Stock Of The Day – Bullish Capitulation In Becton, Dickinson?
Shares of Becton, Dickinson (BDX) staged a large selloff yesterday. There may have been a capitulation. This could be bullish for the stock. 
Via Benzinga
Explore the top gainers and losers within the S&P500 index in today's session.
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session. 
Via Chartmill
Which S&P500 stocks have an unusual volume on Thursday?
Let's have a look at what is happening on the US markets on Thursday. Below you can find the S&P500 stocks with an unusual volume in today's session. 
Via Chartmill
What's going on in today's session: S&P500 movers
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Thursday's session: gap up and gap down stock in the S&P500 index
Curious about the S&P500 stocks that are gapping on Thursday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Potential Tariff Bites Into Becton Dickinson 2025 Profit Outlook, Company Will Invest $2.5 Billion To Boost US Manufacturing
Becton Dickinson trims 2025 EPS outlook on tariffs, reports Q1 sales miss, and confirms $2.5B U.S. manufacturing investment over 5 years. 
Via Benzinga
Topics Earnings World Trade
These S&P500 stocks are moving in today's pre-market session
Get insights into the top gainers and losers in the S&P500 index of Thursday's pre-market session. 
Via Chartmill
BD (NYSE:BDX) Misses Q1 Sales Targets
Medical technology company Becton, Dickinson and Company (NYSE:BDX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 4.5% year on year to $5.27 billion. On the other hand, the... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.